\nMr. Meury is a distinguished pharmaceutical leader with more than 25 years of operational and commercial experience delivering transformative medicines to patients\n<\/p>\n
\nSucceeds current president, chief executive officer, and chairman, Steve Paul, M.D., who will transition to president of research and development and chief scientific officer\n<\/p>\n
\nChristopher Coughlin to assume role of chairman of the board\n<\/p>\n
BOSTON–(BUSINESS WIRE)–$KRTX<\/a>–Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Bill Meury as president and chief executive officer (CEO) and a member of the Company\u2019s board, effective January 3, 2023. Mr. Meury will succeed Steve Paul, M.D., the current president, chief executive officer and chairman, who will transition to president of research and development and chief scientific officer and continue to serve as a member of the board following the effective date. At that time, Christopher Coughlin, the Company\u2019s lead independent director, will assume the role of chairman of the board.\n<\/p>\n <\/a><\/p>\n \n\u201cBill\u2019s appointment as president and CEO is the result of a thoughtful succession plan initiated by Steve\u2019s desire to follow his passion, the science, and focus on the continued growth of Karuna\u2019s research and development efforts. As we considered the natural evolution of the Company, Bill\u2019s leadership and expertise launching and commercializing medicines for psychiatric and neurological conditions was a seamless fit for Karuna, aligning with our strategy for late-stage clinical development and commercialization,\u201d said Mr. Coughlin. \u201cAs we look to the future with Bill as CEO and Steve continuing to oversee our research and development efforts, Karuna is very well positioned for continued success in the coming years.\u201d\n<\/p>\n \nMost recently, Mr. Meury served as a partner at Hildred Capital Management, a private equity firm focusing on the healthcare industry. Previously, he was executive vice president and chief commercial officer at Allergan, where he had responsibility for over 50 products with $16 billion in revenue and over $3 billion in sales and marketing investment. In this role, he led multiple global divisions, including marketing, sales, business analytics, marketing operations, managed care, pricing, and customer service. Prior to this role, he served as Allergan\u2019s president, branded pharma, and executive vice president, commercial, North American brands. He also served as executive vice president, sales and marketing, at Forest prior to its acquisition by Allergan. Mr. Meury serves on the board of directors of Syndax Pharmaceuticals and The Jed Foundation. He received a B.S. in economics from the University of Maryland.\n<\/p>\n \n\u201cKaruna, with a completely novel pharmacological platform, has the potential to transform the way we think about, and treat, complex psychiatric and neurological conditions,\u201d said Mr. Meury. \u201cI have been impressed and inspired by what has been accomplished to date, and I am extremely optimistic about the road ahead as the Company approaches key milestones. I look forward to working alongside Steve, and the incredibly talented Karuna team, as we work toward the same goals \u2013 bringing innovative treatment options to those living with serious mental illness and building the capabilities to be a leading neuroscience company in biopharma.\u201d\n<\/p>\n \n\u201cTo say I am proud of the work we have accomplished to date would be an understatement. As a result of the team\u2019s unwavering commitment, we are on the path to potentially deliver the first new class of medicine for people living with schizophrenia in more than 50 years,\u201d said Dr. Paul. \u201cIn my new role, I will continue to help the team deliver on the promise of KarXT and advance other innovative medicines in our pipeline. I have dedicated my career to solving the challenges of treating serious mental illness and I look forward to continuing my journey with Karuna, partnering with Bill and the rest of my colleagues.\u201d\n<\/p>\n \nAbout Karuna Therapeutics \nForward-Looking Statements Contacts <\/p>\n \nInvestors
\n
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by serious mental illness. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples\u2019 lives. For more information, please visit www.karunatx.com<\/a>.\n<\/p>\n
\n
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our goals to develop and commercialize our product candidates and other statements identified by words such as \u201ccould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or similar expressions and the negatives of those terms. Forward looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our ability to generate positive clinical trial results for our product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, and other risks set forth under the heading \u201cRisk Factors\u201d of our Annual Report on Form 10-K for the year ended December 31, 2021. Our actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.\n<\/p>\n
Alexis Smith
\n
asmith@karunatx.com<\/a>
518-338-8990\n<\/p>\n
![<\/a><\/p>\n\n\u201cBill\u2019s appointment as president and CEO is the result of a thoughtful succession plan initiated by Steve\u2019s desire to follow his passion, the science, and focus on the continued growth of Karuna\u2019s research and development efforts. As we considered the natural evolution of the Company, Bill\u2019s leadership and expertise launching and commercializing medicines for psychiatric and neurological conditions was a seamless fit for Karuna, aligning with our strategy for late-stage clinical development and commercialization,\u201d said Mr. Coughlin. \u201cAs we look to the future with Bill as CEO and Steve continuing to oversee our research and development efforts, Karuna is very well positioned for continued success in the coming years.\u201d\n<\/p>\n\nMost recently, Mr. Meury served as a partner at Hildred Capital Management, a private equity firm focusing on the healthcare industry. Previously, he was executive vice president and chief commercial officer at Allergan, where he had responsibility for over 50 products with $16 billion in revenue and over $3 billion in sales and marketing investment. In this role, he led multiple global divisions, including marketing, sales, business analytics, marketing operations, managed care, pricing, and customer service. Prior to this role, he served as Allergan\u2019s president, branded pharma, and executive vice president, commercial, North American brands. He also served as executive vice president, sales and marketing, at Forest prior to its acquisition by Allergan. Mr. Meury serves on the board of directors of Syndax Pharmaceuticals and The Jed Foundation. He received a B.S. in economics from the University of Maryland.\n<\/p>\n\n\u201cKaruna, with a completely novel pharmacological platform, has the potential to transform the way we think about, and treat, complex psychiatric and neurological conditions,\u201d said Mr. Meury. \u201cI have been impressed and inspired by what has been accomplished to date, and I am extremely optimistic about the road ahead as the Company approaches key milestones. I look forward to working alongside Steve, and the incredibly talented Karuna team, as we work toward the same goals \u2013 bringing innovative treatment options to those living with serious mental illness and building the capabilities to be a leading neuroscience company in biopharma.\u201d\n<\/p>\n\n\u201cTo say I am proud of the work we have accomplished to date would be an understatement. As a result of the team\u2019s unwavering commitment, we are on the path to potentially deliver the first new class of medicine for people living with schizophrenia in more than 50 years,\u201d said Dr. Paul. \u201cIn my new role, I will continue to help the team deliver on the promise of KarXT and advance other innovative medicines in our pipeline. I have dedicated my career to solving the challenges of treating serious mental illness and I look forward to continuing my journey with Karuna, partnering with Bill and the rest of my colleagues.\u201d\n<\/p>\n\nAbout Karuna Therapeutics\nKaruna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by serious mental illness. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples\u2019 lives. For more information, please visit www.karunatx.com<\/a>.\n<\/p>\n\nForward-Looking Statements\nThis press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our goals to develop and commercialize our product candidates and other statements identified by words such as \u201ccould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or similar expressions and the negatives of those terms. Forward looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our ability to generate positive clinical trial results for our product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, and other risks set forth under the heading \u201cRisk Factors\u201d of our Annual Report on Form 10-K for the year ended December 31, 2021. Our actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.\n<\/p>\nContacts <\/p>\n\nInvestorsAlexis Smith\nasmith@karunatx.com<\/a>518-338-8990\n<\/p>\n\nMediaBob Josefsberg\nbjosefsberg@karunatx.com<\/a>646-734-3584<\/p>","protected":false},"excerpt":{"rendered":"Mr. Meury is a distinguished pharmaceutical leader with more than 25 years of operational and commercial experience delivering transformative medicines to patients Succeeds current president, chief executive officer, and chairman, Steve Paul, M.D., who will transition to president of research and development and chief scientific officer Christopher Coughlin to assume role of chairman of the […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-840657","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"\nKaruna Therapeutics Appoints Bill Meury as President and Chief Executive Officer - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer - BeBeez\" \/>\n<meta property=\"og:description\" content=\"Mr. Meury is a distinguished pharmaceutical leader with more than 25 years of operational and commercial experience delivering transformative medicines to patients Succeeds current president, chief executive officer, and chairman, Steve Paul, M.D., who will transition to president of research and development and chief scientific officer Christopher Coughlin to assume role of chairman of the […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-06T17:01:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer\",\"datePublished\":\"2022-12-06T17:01:19+00:00\",\"dateModified\":\"2022-12-06T17:01:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/\"},\"wordCount\":970,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/\",\"name\":\"Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-12-06T17:01:19+00:00\",\"dateModified\":\"2022-12-06T17:01:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer - BeBeez","og_description":"Mr. Meury is a distinguished pharmaceutical leader with more than 25 years of operational and commercial experience delivering transformative medicines to patients Succeeds current president, chief executive officer, and chairman, Steve Paul, M.D., who will transition to president of research and development and chief scientific officer Christopher Coughlin to assume role of chairman of the […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/","og_site_name":"BeBeez","article_published_time":"2022-12-06T17:01:19+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/"},"author":{"name":"","@id":""},"headline":"Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer","datePublished":"2022-12-06T17:01:19+00:00","dateModified":"2022-12-06T17:01:19+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/"},"wordCount":970,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/","name":"Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-12-06T17:01:19+00:00","dateModified":"2022-12-06T17:01:19+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/karuna-therapeutics-appoints-bill-meury-as-president-and-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/840657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=840657"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/840657\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=840657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=840657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=840657"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=840657"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=840657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}](\"https:\/\/mms.businesswire.com\/media\/20221206005265\/en\/718340\/5\/Karuna_TX_-_Logo_-_Standard.jpg\"){kind=link}